Literature DB >> 1537829

Impaired intracellular transport produced by a subset of type IIA von Willebrand disease mutations.

S E Lyons1, M E Bruck, E J Bowie, D Ginsburg.   

Abstract

Type IIA von Willebrand disease (vWD) results from abnormalities in von Willebrand factor (vWF) characterized by absence of plasma high molecular weight (HMW) vWF multimers. In this report, 5 distinct point mutations were identified in 6 Type IIA vWD families. A total of 7 mutations, all clustered within a 124-amino acid segment of the vWF A2 domain, now account for 9 of a panel of 11 Type IIA families. In COS-7 cells, 3 single amino acid substitutions, Val844----Asp, Ser743----Leu, and Gly742----Arg, impaired the transport of vWF multimers between the endoplasmic reticulum and the Golgi complex, with more profound effects on the secretion of HMW multimers than lower molecular weight forms. In contrast, 2 substitutions, Arg834----Trp and Gly742----Glu, resulted in secretion of HMW multimers similar to wild-type vWF. The vWF structure observed within patient platelets correlated closely with the synthesis pattern seen for the corresponding mutants in COS-7 cells. These findings demonstrate that structural alterations within the A2 domain of vWF can produce the characteristic phenotype of Type IIA vWD via two distinct molecular mechanisms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537829

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

2.  Translational medicine advances in von Willebrand disease.

Authors:  D Lillicrap
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

3.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

4.  Mechanisms by which von Willebrand disease mutations destabilize the A2 domain.

Authors:  Amy J Xu; Timothy A Springer
Journal:  J Biol Chem       Date:  2013-01-15       Impact factor: 5.157

5.  Use of a mouse model to elucidate the phenotypic effects of the von Willebrand factor cleavage mutants, Y1605A/M1606A and R1597W.

Authors:  C M Pruss; M Golder; A Bryant; C Hegadorn; S Haberichter; D Lillicrap
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

6.  Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.

Authors:  A Gézsi; U Budde; I Deák; E Nagy; A Mohl; A Schlammadinger; Z Boda; T Masszi; J E Sadler; I Bodó
Journal:  J Thromb Haemost       Date:  2010-01-17       Impact factor: 5.824

7.  Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.

Authors:  Jeffrey J Sutherland; Lee A O'Brien; David Lillicrap; Donald F Weaver
Journal:  J Mol Model       Date:  2004-08-03       Impact factor: 1.810

8.  Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.

Authors:  Kenji Nishio; Patricia J Anderson; X Long Zheng; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

9.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

10.  Proteolytic processing of von Willebrand factor subunit: heterogeneity in type-IIA von Willebrand disease.

Authors:  J Batlle; J Lasierra; A F Villamor; J L Navarro; A Pardo; M Campos; B Justiça; M F López Fernández
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.